文献速递糖尿病肥胖与代谢综合征

肥胖2型糖尿病患者肝脏IRS2表达的多层表观遗传调控

Multi-layered epigenetic regulation of IRS2 expression in the liver of obese individuals with type 2 diabetes.
PubMed 文献 · Diabetologia · 2020-07-24

在50名肥胖非糖尿病者和31名肥胖2型糖尿病者的肝活检中,采用横断面设计检测IRS2基因7个CpG位点甲基化及mRNA/miRNA表达。2型糖尿病者肝脏IRS2表达下调(倍数变化0.84±0.08;p=0.0833;校正p值=0.0417),与CpG5甲基化相关;let-7e-5p上调(倍数变化1.2±0.08;p=0.0332;校正p值=0.0450)。体外实验显示高胰岛素和高糖可急性上调let-7e-5p并下调IRS2。

要点

  • 肥胖2型糖尿病者肝脏IRS2表达下调(倍数变化0.84±0.08;校正p值=0.0417)。
  • IRS2下调与CpG5甲基化相关,CpG6低甲基化,cg25924746甲基化增加。
  • let-7e-5p在2型糖尿病者肝脏上调(倍数变化1.2±0.08;校正p值=0.0450)。

核心结论

  • 研究揭示可能参与2型糖尿病个体肝脏IRS2细微失调的新型多层表观遗传网络,可能对IRS2表达进行微调,并可能是已知调控IRS2表达因素的补充,从而可能支持发现2型糖尿病的新诊断和治疗策略。

研究设计与样本

  • 横断面研究,纳入50名肥胖非糖尿病参与者和31名肥胖2型糖尿病参与者的肝活检。
  • 通过亚硫酸氢盐焦磷酸测序研究7个CpG位点的DNA甲基化,通过定量实时PCR评估mRNA和microRNA表达。
  • 进行甲基化敏感性荧光素酶 assay 和电泳迁移率变动 assay。
  • 用胰岛素和高糖浓度处理HepG2细胞以诱导miRNA表达和IRS2下调。

主要发现

  • 与肥胖非糖尿病参与者(n=50)相比,肥胖2型糖尿病参与者(n=31)肝脏IRS2表达显著下调(倍数变化0.84±0.08;p=0.0833;校正p值[pa]=0.0417)。
  • IRS2下调与肝脏IRS2 CpG5 DNA甲基化相关;位于IRS2内含子1的CpG6在2型糖尿病中低甲基化,该位点跨越固醇调节元件结合转录因子1(SREBF1)识别基序。
  • 相邻多态性rs4547213(G>A)与特异性蛋白1(SP1)结合位点(CpG3)的DNA甲基化显著相关。
  • 位于IRS2启动子相关CpG岛shore区的CpG位点cg25924746的DNA甲基化在2型糖尿病个体肝脏中较非糖尿病者增加。
  • 肥胖2型糖尿病个体(n=29)肝脏miRNA hsa-let-7e-5p(let-7e-5p)较非糖尿病肥胖个体(n=49)上调(倍数变化1.2±0.08;p=0.0332;pa=0.0450),可能与IRS2 DNA甲基化改变协同作用降低IRS2表达。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: IRS2 is an important molecular switch that mediates insulin signalling in the liver. IRS2 dysregulation is responsible for the phenomenon of selective insulin resistance that is observed in type 2 diabetes. We hypothesise that epigenetic mechanisms are involved in the regulation of IRS2 in the liver of obese and type 2 diabetic individuals. METHODS: DNA methylation of seven CpG sites was studied by bisulphite pyrosequencing and mRNA and microRNA (miRNA) expression was assessed by quantitative real-time PCR in liver biopsies of 50 obese non-diabetic and 31 obese type 2 diabetic participants, in a cross-sectional setting. Methylation-sensitive luciferase assays and electrophoretic mobility shift assays were performed. Furthermore, HepG2 cells were treated with insulin and high glucose concentrations to induce miRNA expression and IRS2 downregulation. RESULTS: We found a significant downregulation of IRS2 expression in the liver of obese individuals with type 2 diabetes (0.84 ± 0.08-fold change; p = 0.0833; adjusted p value [pa] = 0.0417; n = 31) in comparison with non-diabetic obese participants (n = 50). This downregulation correlated with hepatic IRS2 DNA methylation at CpG5. Additionally, CpG6, which is located in intron 1 of IRS2, was hypomethylated in type 2 diabetes; this site spans the sterol regulatory element binding transcription factor 1 (SREBF1) recognition motif, which likely acts as transcriptional repressor. The adjacent polymorphism rs4547213 (G>A) was significantly associated with DNA methylation at a specificity-protein-1 (SP1) binding site (CpG3). Moreover, DNA methylation of cg25924746, a CpG site located in the shore region of the IRS2 promoter-associated CpG island, was increased in the liver of individuals with type 2 diabetes, as compared with those without diabetes. A second epigenetic mechanism, upregulation of hepatic miRNA hsa-let-7e-5p (let-7e-5p) in obese individuals with type 2 diabetes (n = 29) vs non-diabetic obese individuals (n = 49) (1.2 ± 0.08-fold change; p = 0.0332; pa = 0.0450), is likely to act synergistically with altered IRS2 DNA methylation to decrease IRS2 expression. Mechanistic in vitro experiments demonstrated an acute upregulation of let-7e-5p expression and simultaneous IRS2 downregulation in a liver (HepG2) cell line upon hyperinsulinaemic and hyperglycaemic conditions. CONCLUSIONS/INTERPRETATION: Our study highlights a new multi-layered epigenetic network that could be involved in subtle dysregulation of IRS2 in the liver of individuals with type 2 diabetes. This might lead to fine-tuning of IRS2 expression and is likely to be supplementary to the already known factors regulating IRS2 expression. Thereby, our findings could support the discovery of new diagnostic and therapeutic strategies for type 2 diabetes. Graphical abstract.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Krause C, Geißler C, Tackenberg H, et al. Multi-layered epigenetic regulation of IRS2 expression in the liver of obese individuals with type 2 diabetes. Diabetologia. 2020. PMID: 32710190. doi:10.1007/s00125-020-05212-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。